@article{a7012f46209d44b9bed97c12a9b51381,
title = "Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD",
abstract = "Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of chronic kidney disease (CKD) and leads to a specific type of bone disease. The primary cilium is a major cellular organelle implicated in the pathophysiology of ADPKD caused by mutations in polycystin-1 (PKD1) and polycystin-2 (PKD2). In this study, for the first time, cilia were characterized in primary preosteoblasts isolated from patients with ADPKD. All patients with ADPKD had low bone turnover and primary osteoblasts were also obtained from patients with non-ADPKD CKD with low bone turnover. Image-based immunofluorescence assays analyzed cilia using standard markers, pericentrin, and acetylated-α-tubulin, where cilia induction and elongation were chosen as relevant endpoints for these initial investigations. Osteoblastic activity was examined by measuring alkaline phosphatase levels and mineralized matrix deposition rates. It was found that primary cilia can be visualized in patient-derived osteoblasts and respond to elongation treatments. Compared with control cells, ADPKD osteoblasts displayed abnormal cilia elongation that was significantly more responsive in cells with PKD2 nontruncating mutations and PKD1 mutations. In contrast, non-ADPKD CKD osteoblasts were unresponsive and had shorter cilia. Finally, ADPKD osteoblasts showed increased rates of mineralized matrix deposition compared with non-ADPKD CKD. This work represents the first study of cilia in primary human-derived osteoblasts from patients with CKD and patients with ADPKD who have normal kidney function, offering new insights as bone disease phenotypes are not well recapitulated in animal models. These data support a model whereby altered cilia occurs in PKD-mutated osteoblasts, and that ADPKD-related defects in bone cell activity and mineralization are distinct from adynamic bone disease from patients with non-ADPKD CKD.",
keywords = "AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BONE, CHRONIC KIDNEY DISEASE, OSTEOBLASTS, POLYCYSTIC KIDNEY DISEASE, PRIMARY CILIA",
author = "Pereira, {Renata C.} and Gitomer, {Berenice Y.} and Michel Chonchol and Harris, {Peter C.} and Noche, {Kathleen J.} and Salusky, {Isidro B.} and Albrecht, {Lauren V.}",
note = "Funding Information: This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK; R01 DK094796). LVA was funded through the A.P. Giannini Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the U.S. Department of Veterans Affairs, or the United States Government. Authors{\textquoteright} roles: Experiment performance: RCP and KN. Genetic analyses: BYG, MC, and PCH. Data analysis: RCP, IBS, and LVA. Manuscript writing, revision, and edit: LVA, RCP, and IBS. Conflict of Interest Dr. Isidro B Salusky reports a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK RO1 DK35423, UO1 DK 119950) and grants from Abbvie and Amgen outside the submitted work. Dr. Michel Chonchol reports grants from the National Institute of Diabetes and Digestive and Kidney Diseases and from the Department of Defense during the conduct of the study, as well as grants from Otsuka, Sanogi, and Kadmon outside the submitted work. Dr. Peter C Harris reports grants from Otsuka Pharmaceuticals and other support from Otsuka Pharmaceuticals, as well as other support from Mitobridge, Regulus, and Vertex Pharmaceuticals outside the submitted work. Funding Information: This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK; R01 DK094796). LVA was funded through the A.P. Giannini Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the U.S. Department of Veterans Affairs, or the United States Government. Funding Information: Dr. Isidro B Salusky reports a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK RO1 DK35423, UO1 DK 119950) and grants from Abbvie and Amgen outside the submitted work. Dr. Michel Chonchol reports grants from the National Institute of Diabetes and Digestive and Kidney Diseases and from the Department of Defense during the conduct of the study, as well as grants from Otsuka, Sanogi, and Kadmon outside the submitted work. Dr. Peter C Harris reports grants from Otsuka Pharmaceuticals and other support from Otsuka Pharmaceuticals, as well as other support from Mitobridge, Regulus, and Vertex Pharmaceuticals outside the submitted work. Publisher Copyright: {\textcopyright} 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.",
year = "2021",
month = apr,
doi = "10.1002/jbm4.10464",
language = "English (US)",
volume = "5",
journal = "JBMR Plus",
issn = "2473-4039",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",
}